Potential Clinical and Economic Value of Long-Acting Preexposure Prophylaxis for South African Women at High-Risk for HIV Infection
Walensky RP, Jacobsen MM, Bekker LG, Parker RA, Wood R, Resch SC, Horstman NK, Freedberg KA, Paltiel AD. Potential Clinical and Economic Value of Long-Acting Preexposure Prophylaxis for South African Women at High-Risk for HIV Infection. The Journal Of Infectious Diseases 2015, 213: 1523-1531. PMID: 26681778, PMCID: PMC4837902, DOI: 10.1093/infdis/jiv523.Peer-Reviewed Original ResearchConceptsStandard prepSouth African womenPreexposure prophylaxisHIV infectionHigh riskHuman immunodeficiency virus (HIV) infectionEffective prevention optionsAfrican womenImmunodeficiency virus infectionCost-saving interventionHIV infection riskYoung South African womenLikely clinical benefitInjectable PrEPPrEP formulationsEligible womenClinical benefitPotential ClinicalVirus infectionOutcome measuresPrEP strategiesProgram costsPrevention optionsSurvival rateGreater adherenceDemographic and clinical features of inclusion body myositis in north America
Paltiel AD, Ingvarsson E, Lee DK, Leff RL, Nowak RJ, Petschke KD, Richards-Shubik S, Zhou A, Shubik M, O'Connor KC. Demographic and clinical features of inclusion body myositis in north America. Muscle & Nerve 2015, 52: 527-533. PMID: 25557419, PMCID: PMC4869122, DOI: 10.1002/mus.24562.Peer-Reviewed Original ResearchConceptsInclusion body myositisBody myositisDaily livingComposite functional indexLarger patient populationWeakness of armsDisease durationClinical featuresInitial diagnosisMean agePatient populationFemale ratioClinical managementClinical trialsOutcome measuresFirst symptomsFunctional indexEarly symptomsNatural historyMean timeSelf-report surveyMyositisPatientsSymptomsDiagnosis